ReproCell Stock

ReproCell Retained Earnings

The Retained Earnings of ReproCell (4978.T) as of Sep 10, 2026 is 58.29 M JPY. In the previous year, Retained Earnings was -543.46 M JPY — a change of -110.73% (higher).

Retained Earnings

58.29 MJPY

YoY

-110.73%

Last updated:

Retained Earnings of ReproCell is 2026 58.29 M JPY. Retained Earnings of ReproCell was 2025 -543.46 M JPY. It decreases by -110.73% higher compared to the previous year.

The ReproCell Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
-6.58 B JPY
Jan 1, 2019
-7.15 B JPY
Jan 1, 2020
-8.22 B JPY
Jan 1, 2021
-9.03 B JPY
Jan 1, 2022
-745.31 M JPY
Jan 1, 2023
-515.46 M JPY
Jan 1, 2024
-543.46 M JPY
Jan 1, 2025
58.29 M JPY
The ReproCell Retained Earnings history
YEARRetained EarningsYoY
58.29 MJPY-110.73%
-543.46 MJPY+5.43%
-515.46 MJPY-30.84%
-745.31 MJPY-91.75%
-9.03 BJPY+9.89%
-8.22 BJPY+14.95%
-7.15 BJPY+8.74%
-6.58 BJPY+48.73%
-4.42 BJPY+25.69%
-3.52 BJPY+139.04%
-1.47 BJPY+53.62%
-957.80 MJPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Retained Earnings of ReproCell is 58.29 M JPY in 2026.

Retained Earnings of ReproCell changed from -543.46 M JPY to 58.29 M JPY, representing a -110.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings ReproCell since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's ReproCell historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ReproCell

All Key Metrics — ReproCell